Connecticut Chronicle

Refractory Angina Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Refractory Angina Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

April 02
17:48 2020
Refractory Angina Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 

DelveInsight has launched a new report on Refractory Angina Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Refractory Angina – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Refractory Angina market report provides current treatment practices, emerging drugs, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Refractory Angina treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Refractory Angina (RA) is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart.Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease(CAD). 

Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms causespoor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization. Patients with RA are a heterogeneous group that remain significantly limited by persistent debilitating chest discomfort despite optimal conventional therapy.

 

Request for :- Free sample page

Epidemiology

The Refractory Angina epidemiology division provide insights about historical and current Refractory Angina patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken

Report key facts:-

1.  As per Delveinsight’s estimates, the total prevalent cases of Refractory Angina in 7 major markets ranges from 29,17,196 in 2017.

2. According to the Delveinsight’s analysts, the United States accounted for most prevalent cases of RA in 7MM with 19,05,602  cases in 2017.

3. Japan accounted for 27,432 cases in 2017 which are expected to grow during the study period (2017–2030).

Refractory Angina (RA)is a chronic disease characterized by the presence of persistent angina and patients with RA defined as being ‘no option’ since they are not considered amenable for conventional revascularization treatment for reasons related to diffuse coronary lesions, unsuitability to chronic total occlusion mechanical revascularization, or frailty from the presence of severe comorbidities

Key companies working on Refractory Angina that are given below:-

1. Imbria Pharmaceuticals

2. Caladrius Biosciences, Inc

3. XyloCor Therapeutics, Inc

Name of drugs covered that are given below:-

1. IMB-101

2. Auto CD34+ Cells

3. XC001

Table of contents

1. Key Insights

2. Executive Summary of Refractory Angina

3. Competitive Intelligence Analysis for Refractory Angina

4. Refractory Angina: Market Overview at a Glance

4.1. Refractory Angina Total Market Share (%) Distribution in 2017

4.2. Refractory Angina Total Market Share (%) Distribution in 2030

5. Refractory Angina: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Refractory Angina Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Refractory Angina Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Refractory Angina Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Refractory Angina Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Refractory Angina Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Refractory Angina Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Refractory Angina Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Refractory Angina Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Refractory Angina Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Refractory Angina Treatment and Management

8.2. Refractory Angina Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Refractory Angina Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Refractory Angina: Seven Major Market Analysis

13.1. Key Findings

13.2. Refractory Angina Market Size in 7MM

13.3. Refractory Angina Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Refractory Angina Total Market Size in the United States

15.1.2. Refractory Angina Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Refractory Angina Total Market Size in Germany

15.3.2. Refractory Angina Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Refractory Angina Total Market Size in France

15.4.2. Refractory Angina Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Refractory Angina Total Market Size in Italy

15.5.2. Refractory Angina Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Refractory Angina Total Market Size in Spain

15.6.2. Refractory Angina Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Refractory Angina Total Market Size in the United Kingdom

15.7.2. Refractory Angina Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Refractory Angina Total Market Size in Japan

15.8.3. Refractory Angina Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Refractory Angina

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Refractory Angina market
  • To understand the future market competition in the Refractory Angina market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Refractory Angina in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Refractory Angina market
  • To understand the future market competition in the Refractory Angina market

Related Reports:-

1. Relapsed or Refractory Mycosis Fungoides – Epidemiology Forecast to 2030

2. relapsed/refractory Epstein-Barr virus (EBV) – Epidemiology Forecast to 2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/